The abrupt cancellation, without warning or cause, has medical groups and health care leaders concerned about patient access to no-cost preventive services.

Key predictors of the severity of self-reported cognitive complaints among nurses going through menopause included symptom severity and climacteric stage.

Bayer's elinzanetant gains UK approval as the first nonhormonal treatment for menopausal symptoms, offering hope to millions of untreated women.

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

Review 9 new FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for migraine, CSU, RSV, and more.

Verekitug is the only biologic in development for COPD that targets the TSLP receptor directly.

Tralokinumab met key trial endpoints with no new safety signals in treatment of moderate-to-severe hand eczema, in adults who are candidates for systemic therapy.

Dr Khanna breaks down the bidirectional relationship and explains why standard pain management often falls short for people with obesity.

A recent study highlights the importance of medication adherence for significant weight loss and improved glycemic control in obesity treatment with GLP-1 agonists.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

Moderna’s Spikevax receives full FDA approval for use in children at increased risk for COVID-19, expanding protection ahead of the 2025–2026 virus season.

TSND-201, a rapid-acting neuroplastogen, demonstrated statistically significant symptom improvement by day 10, which was durable throughout the study until Day 64.

Richard Rosenfeld, MD, MPH, MBA, lead author of new guidelines on sustained lifestyle change as central to treating, even reversing T2D, answers the question.

Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.

The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.

The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Richard Rosenfeld, MD, MPH, MBA, explains how clinical guidelines for diabetes remission from the American College of Lifestyle Medicine differ from and augment existing recommendations.

Your daily dose of the clinical news you may have missed.

Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.